165 related articles for article (PubMed ID: 38836316)
1. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021-December 2023).
Scott JS; Klinowska TCM
Expert Opin Ther Pat; 2024 May; 34(5):333-350. PubMed ID: 38836316
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
Scott JS; Barlaam B
Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
[TBL] [Abstract][Full Text] [Related]
3. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
[TBL] [Abstract][Full Text] [Related]
4. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Wang Y; Tang SC
Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
[TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
6. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
Bhatia N; Hazra S; Thareja S
Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
[TBL] [Abstract][Full Text] [Related]
7. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer.
Chen YC; Yu J; Metcalfe C; De Bruyn T; Gelzleichter T; Malhi V; Perez-Moreno PD; Wang X
Expert Opin Investig Drugs; 2022 Jun; 31(6):515-529. PubMed ID: 34694932
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer.
Guglielmi G; Del Re M; Gol LS; Bengala C; Danesi R; Fogli S
Eur J Pharmacol; 2024 Apr; 969():176424. PubMed ID: 38402929
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
[TBL] [Abstract][Full Text] [Related]
10. Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.
Downton T; Zhou F; Segara D; Jeselsohn R; Lim E
Drug Des Devel Ther; 2022; 16():2933-2948. PubMed ID: 36081610
[TBL] [Abstract][Full Text] [Related]
11. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
Hernando C; Ortega-Morillo B; Tapia M; Moragón S; Martínez MT; Eroles P; Garrido-Cano I; Adam-Artigues A; Lluch A; Bermejo B; Cejalvo JM
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360578
[TBL] [Abstract][Full Text] [Related]
12. Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
Gombos A
Curr Opin Oncol; 2019 Sep; 31(5):424-429. PubMed ID: 31335829
[TBL] [Abstract][Full Text] [Related]
13. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
14. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.
Lu Y; Liu C; Wang X; Liu L; Zhao Z; Liang Z; Liu Y; Wen Z; Du Q; Liu W
Eur J Med Chem; 2023 May; 253():115324. PubMed ID: 37019030
[TBL] [Abstract][Full Text] [Related]
16. From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target.
Mottamal M; Kang B; Peng X; Wang G
ACS Omega; 2021 Apr; 6(14):9334-9343. PubMed ID: 33869913
[TBL] [Abstract][Full Text] [Related]
17. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
McDonnell DP; Wardell SE
Curr Opin Pharmacol; 2010 Dec; 10(6):620-8. PubMed ID: 20926342
[TBL] [Abstract][Full Text] [Related]
18. Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future.
Yao J; Tao Y; Hu Z; Li J; Xue Z; Zhang Y; Lei Y
Front Pharmacol; 2023; 14():1225951. PubMed ID: 37808197
[TBL] [Abstract][Full Text] [Related]
19. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
Wang L; Sharma A
ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
